307 related articles for article (PubMed ID: 26452232)
21. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
Spiegel DM; Khan I; Krishnan M; Mayne TJ
Am J Kidney Dis; 2010 Jan; 55(1):113-20. PubMed ID: 19932539
[TBL] [Abstract][Full Text] [Related]
22. Effect of alternate night nocturnal home hemodialysis on anemia control in patients with end-stage renal disease.
Poon CK; Tang HL; Wong JH; Law WP; Lam CM; Yim KF; Cheuk A; Lee W; Chau KF; Tong MK; Fung SK
Hemodial Int; 2015 Apr; 19(2):235-41. PubMed ID: 25251291
[TBL] [Abstract][Full Text] [Related]
23. The association of the difference in hemoglobin levels before and after hemodialysis with the risk of 1-year mortality in patients undergoing hemodialysis. Results from a nationwide cohort study of the Japanese Renal Data Registry.
Nishiwaki H; Hasegawa T; Koiwa F; Hamano T; Masakane I
PLoS One; 2019; 14(1):e0210533. PubMed ID: 30629677
[TBL] [Abstract][Full Text] [Related]
24. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
[TBL] [Abstract][Full Text] [Related]
25. UK Renal Registry 13th Annual Report (December 2010): Chapter 9: haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2009: national and centre-specific analyses.
Gilg J; Webb L; Feest T; Fogarty D
Nephron Clin Pract; 2011; 119 Suppl 2():c149-77. PubMed ID: 21894032
[TBL] [Abstract][Full Text] [Related]
26. Anemia management and treatment response in patients on hemodialysis: the MAR study.
Portolés J; López-Gómez JM; Aljama P
J Nephrol; 2006; 19(3):352-60. PubMed ID: 16874697
[TBL] [Abstract][Full Text] [Related]
27. [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial].
Saglimbene V; D'Alonzo D; Ruospo M; Vecchio M; Natale P; Gargano L; Nicolucci A; Pellegrini F; Craig JC; Triolo G; Procaccini DA; Santoro A; Di Giulio S; La Rosa S; Murgo A; Di Toro Mammarella R; Sambati M; D'Ambrosio N; Greco V; Giannoccaro G; Flammini A; Boccia E; Montalto G; Pagano S; Amarù S; Fici M; Lumaga GB; Mancini E; Veronesi M; Patregnani L; Querques M; Schiavone P; Chimienti S; Palumbo R; Di Franco D; Della Volpe M; Gori E; Salomone M; Iacono A; Moscoloni M; Treglia A; Casu D; Piras AM; Di Silva A; Mandreoli M; Lopez A; Quarello F; Catizone L; Russo G; Forcellini S; Maccarone M; Catucci G; Di Paolo B; Stingone A; D'Angelo B; Guastoni C; Pasquali S; Minoretti C; Bellasi A; Boscutti G; Martone M; David S; Schito F; Urban L; Di Iorio B; Caruso F; Mazzoni A; Musacchio R; Andreoli D; Cossu M; Li Cavoli G; Cornacchiari M; Granata A; Clementi A; Giordano R; Guastoni C; Barzaghi W; Valentini M; Hegbrant J; Tognoni G; Strippoli GF
G Ital Nefrol; 2013; 30(2):. PubMed ID: 23832463
[TBL] [Abstract][Full Text] [Related]
28. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis.
Kiss Z; Ambrus C; Almasi C; Berta K; Deak G; Horonyi P; Kiss I; Lakatos P; Marton A; Molnar MZ; Nemeth Z; Szabo A; Mucsi I
Nephron Clin Pract; 2011; 117(4):c373-8. PubMed ID: 21071961
[TBL] [Abstract][Full Text] [Related]
29. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
[TBL] [Abstract][Full Text] [Related]
30. Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients.
Evans M; Carrero JJ; Bellocco R; Barany P; Qureshi AR; Seeberger A; Jacobson SH; Hylander-Rössner B; Rotnitzky A; Sjölander A
Nephrol Dial Transplant; 2017 Nov; 32(11):1892-1901. PubMed ID: 27672090
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Lowering Haemoglobin Targets on Patterns of Erythropoiesis-Stimulating Agent Use in Patients on Haemodialysis.
Hazara AM; Owen SJ; Bhandari S
Blood Purif; 2016; 41(4):287-92. PubMed ID: 26820617
[TBL] [Abstract][Full Text] [Related]
32. Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study.
Toida T; Iwakiri T; Sato Y; Komatsu H; Kitamura K; Fujimoto S
PLoS One; 2017; 12(1):e0169117. PubMed ID: 28046068
[TBL] [Abstract][Full Text] [Related]
33. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study.
Portolés J; López-Gómez JM; Aljama P
Nephrol Dial Transplant; 2007 Feb; 22(2):500-7. PubMed ID: 17023492
[TBL] [Abstract][Full Text] [Related]
34. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
[TBL] [Abstract][Full Text] [Related]
35. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
Luo J; Jensen DE; Maroni BJ; Brunelli SM
Am J Kidney Dis; 2016 Nov; 68(5):763-771. PubMed ID: 27528373
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of mid-week hemoglobin measurement for anemia management in patients undergoing hemodialysis: a retrospective cohort study.
Bae SY; Jeon JW; Kim SH; Baek CH; Jang JW; Yang WS; Kim SB; Park SK; Lee SK; Kim H
BMC Nephrol; 2019 Aug; 20(1):295. PubMed ID: 31375077
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.
Minutolo R; Bolasco P; Chiodini P; Sposini S; Borzumati M; Abaterusso C; Mele AA; Santoro D; Canale V; Santoboni A; Filiberti O; Fiorini F; Mura C; Imperiali P; Borrelli S; Russo L; De Nicola L; Russo D
Clin Drug Investig; 2017 Oct; 37(10):965-973. PubMed ID: 28779268
[TBL] [Abstract][Full Text] [Related]
38. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
39. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
[TBL] [Abstract][Full Text] [Related]
40. UK Renal Registry 11th Annual Report (December 2008): Chapter 9 Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analyses.
Richardson D; Ford D; Gilg J; Williams AJ
Nephron Clin Pract; 2009; 111 Suppl 1():c149-83. PubMed ID: 19542697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
